ANTI-INFECTIVE

AGENTS

Disposition of Cefpodoxirne Proxetil in Hemodialysis Patients T. Bonn,

Marie

Bruce

PhD,

E. Shapiro,

George

MD,

S. Hughes,

and

Charles

MD,

FCP,

Judy

S. Kelloway,

E. Halstenson,

PharmD,

PharmD,

FCP

The disposition of cefpodoxime after single, oral 200-mg doses of cefpodoxime proxetil (cefpodoxime equivalents) was investigated in an open-label study of six patients with end-stage renal disease currently maintained on hemodialysis. Subjects were randomly assigned to one of two treatment groups, which differed in the sequence of the interdialytic and intradialytic periods. Doses were separated by at least 2 weeks. Blood samples were serially collected for 48 hours after each treatment; if obtainable, urine was also collected over this same period. During the intradialytic period, hemodialysis was scheduled to begin approximately 3 hours after dosing, and dialysate was collected before and until the end of dialysis. Average cefpodoxime elimination half-life for the interdialytic period was 18.0 ± 6.5 hours; apparent total body clearance was 28.6 ± 13 mL/minute. The half-life during hemodialysis, 2.66 ± 0.74 hours, was considerably shorter than that after hemodialysis, 19.2 ± 3.5 hours, in the intradialytic period of the study. Hemodialysis clearance of cefpodoxime was 120 ± 31 mL/minute, which was 57.1 ± 13% arid 71.7 ± 25% of the hemodialysis clearance for urea nitrogen and creatinine, respectively. The 2.86 ± 0.25 hour hemodialysis session removed 22.4 ± 2.9% of the administered dose, as assessed by cefpodoxime recovery in dialysate. A maximum rebound in cefpodoxime plasma concentration of 0.41 ± 0.33 mcg/mL was observed, at about one-half hour after the end of hemodialysis. Based on these results, dosage adjustment is not required, but extension of the dosing interval is warranted. The recommended dosing interval for cefpodoxime proxetil in patients with end-stage renal disease is three times a week, after hemodialysis.

C efpodoxime

proxetil (U-76252), an orally active cephalosporin antibiotic, is a prodrug that is deesterified in vivo to its biologically active metabolite, cefpodoxime (U-76253), which has in vitro activity against many common gram-positive and gram-negative bacteria. Conversion of the orally administered prodrug to active cefpodoxime is believed to be mediated by nonspecific intestinal brush border esterases.1’2 Cefpodoxime exerts its antibacterial activity by binding to penicillin-binding proteins, thereby causing abnormal bacterial wall synthesis and lysis.’ Clinical studies have shown the efficacy of cefpodoxime proxetil for treatment of urinary tract infec-

tions, gonorrhea, and upper and The disposition

structure infections, tract infections.413 proxetil has been studied in patients with mild to severe renal impairment.14’15 The results of these studies indicated that cefpodoxime half-life in patients with moderate and severe that

Minnesota. Address for reprints: pany, 7215-24-2, 301 Henrietta

1fl20

-

i

flht

flLI

Marie T. Bonn, PhD, The Upjohn ComStreet, Kalamazoo, Ml 49007.

lflflfl.’fl.1fl’O

dysfunction volunteers,

was prolonged and apparent

relative

to

total body clearance and renal clearance declined as renal function diminished. Dosage adjustment in patients with creatinine clearance less than 50 mL/min was in

recommended. Hemodialysis

stage From the Clinical Pharmacokinetics Unit (Dr. Bonn) and the Clinical Research Unit (Dr. Hughes), The Upjohn Company, Kalamazoo, Michigan; The Drug Evaluation Unit, Hennepin County Medical Center (Drs. Kelloway, Shapiro, and Halstenson) and the College of Pharmacy, University of Minnesota (Drs. Kelloway and Halstenson), Minneapolis,

renal normal

skin and skin lower respiratory of cefpodoxime

mented

renal three

is warranted

failure. times

This

in

patients

procedure

a week,

and

the

with

end-

is typically

imple-

duration

of each

dialysis is about 3 hours. Hoffler et al.16 investigated the pharmacokinetics of cefpodoxime pro xetil in patients with end-stage renal disease undergoing hemodialysis. A parallel design was used with respect to interdialytic and intradialytic treatment groups. Serum cefpodoxime concentrations in hemodialysis

DISPOSITION

OF

CEFPODOXIME

PROXETIL

IN

ing the fasting patients were much higher than in healthy volunteers, and cefpodoxime was dialyzable. Based on these findings, a modified dosage schedule was recommended for hemodialysis patients. The current study was conducted to further evaluate the effect of end-stage renal disease on the disposition of cefpodoxime after a single, oral 200-mg dose of cefpodoxime proxetil (cefpodoxime equivalents) using a crossover design with respect to interdialytic and intradialytic periods. Thus, the same subjects were dosed on an off-dialysis day and a few hours before hemodialysis to obtain reliable estimates of the dialytic clearance rate and the extent to which cefpodoxime is dialyzed. MATERIALS

AND

METHODS

Subjects Six adult volunteers enrolled in the study after giving written informed consent. Subjects participated in the study after giving a medical history and undergoing a physical examination, an electrocardiogram, and clinical laboratory tests. Subjects who had received known enzyme-inducing agents, theophylline, cimetidine, metoclopramide, or similar drugs within 30 days or antibiotics within 10 days of study initiation were excluded. No caffeine or caffeinecontaining substances were allowed for 48 hours before or throughout the study. All subjects refrained from alcohol 1 day before and until study completion. Concurrent drug therapy considered necessary for the volunteer’s welfare was permitted. This included drugs associated with dialysis and drugs for the treatment of anemia, chronic cardiovascular disorders, gastrointestinal discomfort, allergies, pain, insomnia, and hypoparathyroidism. Diet supplements and aids for smoking cessation also were allowed. Aluminum hydroxide-containing antacids, Shohl’s solution, or calcium supplements were not taken 4 hours before or for 4 hours after dosing. Drug

Administration

Subjects took single, oral 200-mg doses of cefpodoxime proxetil (dose expressed in cefpodoxime equivalents) on two occasions separated by at least 2 weeks. Subjects were randomized to one of two treatment groups, which differed in the sequence of being treated between periods of dialysis (interdialytic period) or during dialysis (intradialytic period). Each subject took two cefpodoxime proxetil 100-mg tablets (Lot #25,267, The Upjohn Co., Kalamazoo, MI) orally with 6 ounces of water after an overnight fast. Fasting was continued for 4 hours after dosing. Dur-

*p.rri

IMrI”rIt,r

A,’rRrro

water

was

Sample

HEMODIALYSIS

period,

no food

or beverage

other

than

allowed.

Collection

Blood samples (7 mL) were collected in lavendertopped tubes (Becton-Dickinson, Rutherford, New Jersey) containing freeze-dried ethylenediaminetetra-acetic acid as anticoagulant. During the interdialytic and intradialytic phases, samples were obtained immediately before dosing (0 hour) and at the following times after dosing: 0.33, 0.67, 1, 1.5, 2, 2.5, and 3 hours. Additional blood samples were collected at 4, 6, 8, 10, 12, 16, 20, 24, 36, and 48 hours after dosing in the interdialytic period. Hemodialysis with a single-pass dialysis machine was scheduled to begin approximately 3 hours after drug administration, and arterial (predialysis filter) and venous (postdialysis filter) blood was collected at 0.5, 1, 2, and 3 (or end of dialysis) hours after the start of dialysis. Venous blood only then was obtained at the following times relative to the end of dialysis: 0.17,0.33, 0.50, 0.75, 1, 2, 4, 6, 10, 14, 18, 30, and 42 hours. Plasma was harvested from each specimen, frozen on dry ice, and stored at -20#{176}Cuntil assayed. Urine was collected from all subjects who were not anuric before dosing (-12 to 0 hour) and for 48 hours after dosing in the following intervals: 0 to 6, 6 to 12, 12 to 24, 24 to 36, and 36 to 48 hours. During each collection period, the urine flask was stored at 4#{176}C. Urine volumes were quantitated, and an aliquot was saved and frozen at -20#{176}Cuntil analysis. During the intradialytic period, a dialysate sample was collected before the start of hemodialysis and then at the following intervals: 0 to 0.5, 0.5 to 1, 1 to 1.5, 1.5 to 2, 2 to 2.5, 2.5 to 3, and 3 hours to end of dialysis. Dialysate volumes were recorded and an aliquot of each collection was stored at -20#{176}Cuntil assayed. Analytical

Procedure

Concentrations of cefpodoxime in plasma, urine, and dialysate samples were determined by a microbiologic method.17 Quantitation of cefpodoxime was based on the diffusion of 30-1iL samples from 6-mm wells into Antibiotic Medium #1 (Difco) seeded with 0.15% (vol/vol) Providencia rettgeri, UC-12186 (CDC #4334-69, Bronson Methodist Hospital, Kalamazoo, MI). Zones of inhibition were measured and read against the standard curve. The assay was linear over the cefpodoxime concentration range of 0.05 to 1.28 ig/mL and showed a mean recovery of 94%, maximum within-run precision of 3.9%, and between-run precision of 8.0%. Samples with drug 1ev-

I 11fl

BORIN

ET

els greater than 1.28 g/mL were diluted with either pooled plasma or phosphate-buffered saline to obtain a linear standard curve. Specificity of this microbiologic method for cefpodoxime has been demonstrated previously in studies comparing high-pressure liquid chromatography and microbiologic assay results; excellent correlations between the two methods were observed for cefpodoxime levels in plasma and in urine, with close agreement between assay concentrations.18 Additionally, cefpodoxime undergoes minimal biotransformation in humans,19 which greatly reduces the potential for assay bias due to active metabolites. Pharmacokinetic

Analysis

Pharmacokinetic parameters were calculated using noncompartmental methods. Terminal elimination rate constants (k0J were estimated by least squares regression of log-transformed cefpodoxime plasma concentration-time data in the terminal linear phase. For the interdialytic period, regressions were carried out using the 12- to 48-hour post-dose samples. The terminal elimination half-life (t#{189}) was calculated as 0.693/k01. Plasma cefpodoxime area under the concentration-time curve from time 0 to infinity (AUC) was estimated using the trapezoidal rule for time 0 to the last measured plasma concentration and then extrapolating to infinity by adding the last measured plasma concentration divided by k01. Apparent cefpodoxime total body clearance (CL,jF) was calculated as the dose divided by AUC0. The absorption rate constant (k0) was determined using the Wagner-Nelson method. The lag time to beginning of absorption (tiag) was estimated by nonlinear regression analysis of the fraction absorbed (fa) versus time data fitted to the following relationship:

TABLE Subject Subject

No.

Sex

Demographic

Race

1040

Black,

S

-

RESULTS Subjects participating in the study ranged in age from 37 to 66 years (mean, 50.7 years) and in weight from 50.0 to 106 kg (mean, 74.7 kg). Individual subject demographics are listed in Table I. Mean plasma cefpodoxime concentration-versustime data are shown in Figure la and lb. Individual subject pharmacokinetic parameters for the interdialytic period are summarized in Table II, and intradialytic parameters are displayed in Table III. Pharmacokinetic parameters for the posthemodialysis period appear in Table IV. The time that patients were on hemodialysis ranged from 2.5 to 3.1 hours (Table V).

I Characteristics Age (yr)

Weight

(kg)

Height

(cm)

M M M

B C C

41 45 56

70.5 74.1 106

175 180 188

4

F M F

A C C

59 37 66

81.8 65.5 50.0

50.7 11.4

74.7 18.7

160 173 168 174

Mean SD =

= I e -t-t The apparent volume of distribution (Vd/F) was determined as CL/k01. The maximum plasma concentration of cefpodoxime (Cmax) and the time to achieve maximum concentration (tmax) were estimated by visual inspection of individual concentration-time profiles. Urinary excretion of cefpodoxime was determined by multiplying urine concentrations by the corresponding urine volume values. The amount of drug recovered in the dialysate (AD) was similarly calculated. Renal clearance of cefpodoxime (CLPJ was calculated as Ae8/AUC0, where Ae is the amount of cefpodoxime recovered in the urine from time 0 to time 48 hours and AUC is the area under the plasma concentration-versus-time curve during the same time interval. Dialysis clearance (CL) was determined as AD/AUCHD where AUCHD is the area under the prefilter plasma concentration-time curve during hemodialysis. Dialyzer creatinine (CLCPJ and urea nitrogen (CLBUN) clearances were similarly calculated.

1 2 3

5 6

B

AL

C

=

Caucasian,

J Clin Pharmacol

A

=

Native

American.

1992;32:1038-1044

9.7

DISPOSITION

OF’ CEFPODOXIME

PROXETIL

IN

HEMODIALYSIS

a IT

-J

)(

??9o

i

1001

0’

OU

110

0I

j

10

1.000 o2 Et 00 .2#{176}

1

0

0.100 10

20 Time

40

30

50

(hours)

20

Time

Figure

1. Mean

intradialytic

During

plasma period.

cefpodoxime

hemodialysis,

considerably

shorter

concentration-time

half-life

cefpodoxime than

in

the

profiles

interdialytic

for six subjects

was

and CL0 was much higher, indicating efficient removal of the drug during hemodialysis. Cefpodoxime CLHD was 71.7 ± 25% and 57.1 ± 13% of the hemodialysis clearance for creatinine and urea nitrogen, respectively. These values represent the approximate rate at which cefpodoxime is cleared by the dialyzer relative to creatinine and urea nitrogen removal. The amount of drug recovered in the dialysate was 22.4 ± 2.9% of the administered dose. After cessation of hemodialysis, the maximum increase in cefpodoxime plasma concentration ranged from 8.8% to 77% and occurred at approximately 30 minutes in 5 of the 6 subjects. Rebound parameters could

TABLE Interdialytic

Cefpodoxime

Pharmacokinetic

Parameters

(a) during

not be estimated sis

period

dosed

arterial

half-life hours, during

after which the

an interdialytic

in one

sample

(hours)

subject

was

not the

period

an

a post-dialyCefpodoxime

averaged to

interdialytic

or (b) during

because collected.

hemodialysis is similar

period,

19.2

mean

value

(18.0

± 6.5

± observed

3.5

hours).

DISCUSSION Cefpodoxime

is a cephalosporin

that

has

low

by renal excretion.19 It has been demonthat the elimination of cefpodoxime is deon renal function.15 The results of the study in patients with end-stage renal dis-

are

consistent

with

to 23%)

is eliminated

primarily

ease

(18

and

protein

strated pendent current

binding

agent

plasma

this

finding.

Cefpodoxime

II After

a Single

200-mg

Dose of Cefpodoxlme

Proxetil

Subje ct No. Parameter

Cmax

1

(mcg/mL)

tmax(hr) tuag(hr)

ka (hr’) k01, (hn) (hr) AUC(mcg-hr/mL) CL/F(mL/min) t’/2

Fe(%) CLR (mL/min)

Vd/F

(L/kg)

ANTI-INFECTIVE

AGENTS

2

3

4

5

6

Mean

4.13 4.00

3.53 8.00

6.32 6.05

5.94 6.05

4.76 5.02

5.18

3.45

2.00

4.00

0.41 1.66 0.052

0.30

0.57

0.691 0.062

0.775 0.032

13.4 107 31.1

11.3 68.6

21.9 136

48.6

24.6

8.54 2.89 0.498

2.03 1.05 0.639

0.00

0.36

0.05

SD

1.24 2.11 0.22

0.28

0.363

0.539

0.783

0.80

0.049

0.024 28.5

0.037 18.6 176

0.043 18.0 140

19.0

14.0

Anunic

92.8 35.9 0.42

263 12.7 Anuric

2.10

28.6 3.27

1.14 0.439

0.17 0.516

Anuric 0.479

0.49 0.611

1.15 0.530

1

0.449 0.014 6.47 70.4 12.8

3.60 1.05 0.078

1041

TABLE Intradlalytic

Cefpodoxime

Pharmacokinetic

Parameters

III After

Subject

a Single

200-mg

Dose of Cefpodoxlme

Proxetil

No.

Parameter

1

2

3

4

5

6

Mean

SD

Cmax (mcg/mL) tmax (hr) k51-HD (hr’) t1/2-HD (hr) AUC(mcg.hr/mL) CLHD(mL/min)

3.37

3.28

3.87

2.00

2.50

3.00

2.71 3.00

0.248

0.429

0.243

4.95 2.00 0.183 3.79 8.25 109 1.12

3.51 2.58 0.280 2.66 6.10 120 1.10

0.82 0.49 0.086 0.74 1.27 30.8 0.67

0.328

2.12 5.61

F5 (%) CLR (mL/min) A(mg) AD (% of dose)

2.79 6.83

126

112

1.99

0.89 1.05 46.0 23.0

1.86

42.3 21.1

1.62 5.96 70.9 Anunic

2.85 5.20 142 0.39

2.85 3.00 0.250 2.78 4.75 161 Anuric

Anuric

0.32

Anunic

0.52

0.94

0.69

44.2 22.1

45.8 22.9

54.1 27.1

44.7 22.4

5.88 2.94

36.0 18.0

elimination half-life in hemodialysis patients (18.0 ± 6.5 hours) was much higher than that reported in patients with severe renal impairment (9.8 ± 1.2 hours).15 The AUC,D was higher and CL/F was lower in hemodialysis patients than in subjects with severe renal impairment. Apparent volume of distribution was similar to previous estimates in normal volunteers (0.70 L/kg) and subjects with mild to severe renal impairment (0.57 to 0.80 L/kg),15 which is consistent with the low protein binding of cefpodoxime. Patients with end-stage renal disease on an interdialytic day had a higher Cmax and prolonged tmax relative to healthy volunteers and patients with mild to severe renal impairment. The tieg and k5 estimates were comparable among all subject groups.

The absolute bioavailability of cefpodoxime proxetil is about 5#{216}%20 Although the apparent increase in Cmax and tmax for patients with end-stage renal disease relative to healthy volunteers and patients with mild to severe renal dysfunction may be due to increased drug absorption, it is more likely to be related to a reduction in elimination of cefpodoxime, because Vd/F was unchanged. In those hemodialysis patients who were able to produce urine, urinary excretion and renal clearance of cefpodoxime were much lower than in patients with less impairment of renal function, as expected for a compound that is cleared primarily by renal mechanisms. The results of this study are in agreement with the findings reported previously for hemodialysis patients dosed either off dialysis or during dialysis.16

TABLE Post-Hemodialysis

Period

Pharmacokinetic Subject

Parameter

Maximum change Cp8 (mcg/mL) Percent tmax(hr) k, (hr’) t1/2 (hr) * Cp t ND

1042

increase

=

5

Parameters

No.

1

2

3

4

5

6

Mean

SD

0.68 77.3

0.25 19.7

NDt ND

0.14 11.6

0.15 8.77

0.85 42.5 0.75 0.040 17.1

0.41 32.0 0.52 0.037 19.2

0.33 28.6 0.23 0.007 3.52

in in Cp

0.50

=

IV

ND

0.68

0.50

0.049

0.032

24.3

14.2

21.5

0.035 19.8

0.038 18.3

plasma cefpodoxime concentration. not determined; post-dialysis arterial

J CIin Pharmacol

0.17

0.029

sample

1992;32:1038-1044

not drawn.

TABLE Hemodlalysis*

V Parameters

Subject Parameter

1

2

3

4

5

6

3.00

3.08

2.97

3.02

2.50

2.58

Mean

SD

Time on dialysis (hr)

Dialysate rate

Plasma rate Dialyzer

0.25

(mL/min)

704

499

506

487

517

543

543

81

flow (mI/mm)

250

291

217

304

279

295

273

33

176

220

205

225

240

196

210

22.8

114

167

192

194

191

188

174

31.2

CLBUN

(mI/mm) Dialyzer CLCR (mL/min) *

2.86

flow

Travenol

CA2I 0 dia!yz er filter

used for a II subjects.

The disposition of cefpodoxime proxetil in patients with end-stage renal disease is similar to that of other oral cephalosporin agents, such as cefprozil, cefetamet pivoxil, and cefotiam hexetil.223 Cefpodoxime is dialyzable to a greater extent than cefixime but less than cefprozil during a 3-hour hemodialysis procedure.21’24 Because Vd/F is unchanged in patients with endstage renal disease maintained on hemodialysis, the dose of cefpodoxime proxetil need not be altered from that in patients with normal renal function. To avoid accumulation of drug, the frequency of dosing

should be reduced. Cefpodoxime plasma concentrations were simulated with the super-position principle using mean data from the intradialytic and interdialytic periods and a dosing schedule in which patients receive a 200-mg dose of cefpodoxime proxetil three times a week after dialysis (Figure 2). This regimen provides a mean peak concentration of 4.9 sg/ mL and trough levels exceeding 0.37 zg/mL, which are above the M1C90 for most organisms in cefpodoxime’s antibacterial spectrum. In summary, the disposition of cefpodoxime proxetil is altered in the presence of end-stage renal disease. Hemodialysis removed about 22% of the administered dose. Because of the prolonged elimination half-life of cefpodoxime but an unchanged Vd/F in hemodialysis patients, dosage adjustment is not required, but extension of the dosing interval is warranted. It is recommended that cefpodoxime proxetil be administered three times a week after hemodialysis to provide trough concentrations exceeding 0.37 ig/mL for a 200-mg dose.

The authors thank the Drug Evaluation tance.

the staff of the Clinical Unit and Sheila O’Meara

Research Section of for secretarial assis-

REFERENCES

Figure 2. Simulated files after niultiple administered three

ANTI-INFECTIVE

plasma cefpodoxime concentration-time oral doses of 200 mg of cefpodoxime times a week after hemodialysis.

AGENTS

proproxetil

1. Jones RN, Barry AL: Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother 1988:32:443-449.

1043

BORIN

2. Komai T, Kawai K. Tsubake H, Tokui T, Kinoshita T, Tanaka M: Absorption, distribution, metabolism, and excretion ofCS-807, a new oral cephem antibiotic, in experimental animals. Chemotherapy (Tokyo) 1988: 36(Suppl. I ):229-240.

ET

AL

ance crob

in adults Chemother

from respiratory tract 26(Suppl. E):93-101.

suffering 1990;

14.

Ueda S. Hayashi shitake N, Noda 5, CS-807. Chemotherapy

infections.

JAntimi-

K, Okabi T, Yoshizumi 0, Yamashita T, YoEto K: Fundamental and clinical studies on (Tokyo) 1988; 36(Suppl. I ):859-867.

3. Yakota T, Suzuki E. Aria K: Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins. and synergy of bactericidal activity with serum complement and mouse-cultured macrophages. Drugs Exp Clin lies 1988;16:495-500.

15. St. Peter JV, Bonn MT. Hughes CS, Kelloway IS, Shapiro BE, Halstenson CE: Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function. Antimicrob Agents Chemother 1992; 36:126-131.

4. Fujii A. Maeda H, Yamazaki H, Arakawa S, Kamidono cal studies on CS-807 in the urological field. Chemotherapy kyo) 1988;36(Suppl. 1):788-801.

16. Hoffler D, Koeppe proxetil in patients 1990; 18:157-162.

5. Yamasaki A. Seo K. Sanda N, Seko CS-807 in urinary tract infections. 1988; 36(Suppl. 1):813-818.

S. Nakano

5: Clini(To-

H,

Nihira

Chemotherapy

H:

(Tokyo)

17.

Patel

RK:

18.

8. Matsumoto tions of the

20. Tremblay macokinetics

T, Matsuda skin.

T, Urabe

Chemotherapy

H: CS-807

(Tokyo)

1988;

in bacterial 36(Suppl.

infec1):1106-

I, Yamaji

E, Kawamura

H, Kawaguchi

i-I. Akieda

Watanabe T, Suzuki T, Itokawa K, Veno K, Watamabe zawa T: Clinical application of CS-807, an oral cephalosporin biotic. to skin and soft tissue infections. Chemotherapy 1988; 36(Suppl. I ):620-647.

10.

Hiroyoshi

tract 423. 11.

K, Kudo Chemotherapy

I. Ohnuma

Hayashi

of

infection. Safran

chronic

K, Kabe (Tokyo)

K: Clinical bronchitis.

J: CS-807

in

1988;36(Suppl.

results of CS-807 Chemotherapy

Y.

K, Kanaanti(Tokyo)

respiratory 1):419-

on acute (Tokyo)

exac1988;

K. Shimizu

Chemotherapy

C: Cefpodoxime

#{149} J Clin Pharmacol

Y, Shiota (Tokyo)

K: CS-807 1988; 36(Suppl.

proxetil:

Dosage,

1992;32:1038-1044

in respiratory 1):51 5-521.

efficacy

and

tract

toler-

MT.

and

Abstr. 1990;

Hughes CS, and tolerance

Przyklink renal

validation

of

90th meeting abstr. #A142.

Patel RK, studies

A: Cefpodoxime failure. Infection microbioassay

of the American

for

Soci-

Royer ME, Cathcart KS: Pharof cefpodoxime after single-

and multiple-dose oral administration of cefpodoxime proxetil. Clin Pharmacol 1991:31:1137-1145. 19. Bonn MT: A review of the pharmacokinetics of cefpodoxime proxetil.

Drugs

1991

;42(Suppl.

3):13-21.

D, Dupront A, Ho C. Coussediere of cefpodoxime in young and

single

doses.

I Antimicrob

Chemother

D, Lenfant B: Pharelderly volunteers 1990;

26(Suppl.

E):21-

28. 21.

Shyu

WC,

Pittman

KA,

Wilber

Pharmacokinetics of cefprozil with renal impairment. J Clin

RB,

Matzke

in healthy Pharmacol

CR,

Barbhaiya

subjects

and

RH:

patients

1991;31:362-371.

J, Tam YK, Blouin RA, Frey FJ, Keller E, Stathakis C, Luginbuehl B. Stoeckel K: Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother 1989; 33:1952-1957. 23. Koeppe P, Hoffler D, Mattiucci M, Kienle E: Pharmacokinetics in healthy volunteers and patients with impaired renal function after oral cefotiam hexetil. Acta Therapeutica 1989:15:337-354. 24. Guay DRP, Meatherall RC, HardingGK, Brown CR: Pharmacokinetics of cefixime (CL 284.635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 22.

1):386-390.

12. Kobayashi

1044

I, Ohia

infections.

erbation 36(Suppl.

13.

Bonn macokinetic

after

1110.

9. Nakayama

Development

cefpodoxime. Program ety for Microbiology.

6. Takizawa K, Ino Y, lguchi T. Takeda Y: Antibacterial and clinical effects of a newly synthesized antibiotic, CS-807, in gynecological infections. Chemotherapy (Tokyo) 1988; 36(Suppl. 1):903-906. 7. Hoshino M. Mogi S. Takahashi H: Clinical evaluation of CS-807 against skin and soft tissue infections. Chemotherapy (Tokyo) 1988;36(Suppl. 1):1074-1078.

P. Corcilius M, with endstage

Kneer

1986:30:485-490.

Disposition of cefpodoxime proxetil in hemodialysis patients.

The disposition of cefpodoxime after single, oral 200-mg doses of cefpodoxime proxetil (cefpodoxime equivalents) was investigated in an open-label stu...
983KB Sizes 0 Downloads 0 Views